Varian Medical acquires software developer

Article

Argus Software, a supplier of specialized radiotherapy and diagnostic imaging software, has become part of the oncology systems business of Varian Medical Systems. The privately held company's software automates the collection of quality control and test

Argus Software, a supplier of specialized radiotherapy and diagnostic imaging software, has become part of the oncology systems business of Varian Medical Systems. The privately held company's software automates the collection of quality control and test data for radiation equipment. Details of the acquisition, which was announced Jan. 16, were not disclosed. Argus software will be added to Varian's radiation oncology products, according to the company. The acquisition could reduce Varian's time-to-market for future products, including a software module capable of automating intensity-modulated radiation therapy (IMRT), the company said. This module could accelerate the clinical adoption of IMRT, which is already moving fast. The number of cancer centers offering Varian's IMRT product SmartBeam more than doubled to 92 in 2001 from 40 the year before.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.